Blood CancerArchives
Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospects
Blood Cancer 1 min.
The greatest hindrance to long-lasting remission in multiple myeloma (MM) is drug resistance and is modulated by the complex interaction of tumor-intrinsic plasticity and microenvironmental co-evolution. Multi-omics of single cells has transformed the exploration of this complexity, and has solved the...
Acute pancreatitis revealing adult lymphocytic leukemia in a patient with double cystic duct: a rare case report
Blood Cancer 1 min.
Chronic lymphocytic leukemia (CLL) is an indolent B-cell lymphoproliferative disorder often discovered incidentally through routine blood tests. Acute pancreatitis (AP) is a common abdominal emergency, typically of biliary or alcoholic etiology. We report an unusual case of a 63-year-old woman presenting...
Immune-related genes for the prediction of response to imatinib therapy in chronic myeloid leukemia
Blood Cancer 1 min.
Chronic myeloid leukemia (CML) is a malignant hyperplastic tumor that originates from pluripotent hematopoietic stem cells in the bone marrow. The introduction of tyrosine kinase inhibitors has significantly improved the survival rates of CML patients. This study aimed to identify immune-related genes...
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
Blood Cancer 1 min.
Although myeloma represents a key success story in oncology, some drugs have failed to meet primary endpoints in randomized controlled trials (RCTs), despite promising early phase activity. This analysis aimed to understand factors that increase the likelihood of meeting primary endpoints in myeloma...
Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches
Blood Cancer 1 min.
Hepatitis E virus (HEV) is an under-recognized cause of viral hepatitis, with rising incidence in high-income countries largely driven by zoonotic transmission. Patients with multiple myeloma (MM) are especially vulnerable to HEV, yet there have been no recommendations for antiviral treatment or on its...
